

Mesagut

Mesalazine BP 400 mg

Composition:

Mesagut Tablet: Each delayed release tablet contains Mesalazine BP 400 mg.

Pharmacology:

Mesalazine diminishes inflammation by blocking cyclooxygenase & lipoxygenase and inhibiting prostaglandin & leukotrienes production in the colon.

Indications:

- Treatment of mild to moderate Ulcerative Colitis
- Maintenance of remission of mild to moderate Ulcerative Colitis
- Maintenance of remission of Crohn's disease

Dosage and Administration:**Treatment of mild to moderate Ulcerative Colitis**

Adult: For adults, the recommended dosage of Mesagut is 800 mg (two 400 mg tablets) three times daily for a duration of 6 weeks. However, a dose up to 4.8 g/day in divided doses may be given if needed.

Child: For child patients 5 years of age and older, daily dosage of Mesagut is as follows:

Weight Group (kg)	Morning Dosage	Evening Dosage	Duration
17 to <33	two 400 mg tablets	one 400 mg tablet	6 weeks
33 to <54	three 400 mg tablets	two 400 mg tablets	

Maintenance of remission of mild to moderate Ulcerative Colitis

Adult: The recommended dosage of Mesagut is 1.6 g (four 400 mg tablets) daily in two to four divided doses. However, a dose up to 2.4 g/day in divided doses may be given if needed.

Maintenance of remission of Crohn's disease

Adult: 1.2-2.4 g daily in divided dose.

Child: 400-800 mg 3 times daily.

Contraindications:

Mesalazine is contraindicated in patients with known hypersensitivity to salicylates or aminosaliclates or to any of the ingredients of Mesalazine.

Side effects:

The common side effects are nausea, vomiting, dizziness, asthenia, dyspepsia, rash, fatigue, pruritis etc.

Precautions:

Renal Impairment: Evaluate renal function in all patients prior to initiation and periodically while on mesalazine therapy.

Hepatic Impairment: Evaluate the risks and benefits of using mesalazine in patients with known liver impairment.

Use in special groups:

Pregnant Women: It should be given in pregnancy only if the potential benefit justifies the potential risk to the foetus.

Lactating mother: Caution is advised when it is administered to a nursing women.

Geriatrics: Patients who are 65 years or older, caution should be taken to closely monitor blood cell counts during mesalazine therapy.

Drug Interactions:

The concurrent use of mesalazine with known nephrotoxic agents, including NSAIDs may increase the risk of nephrotoxicity & use of mesalazine with azathioprine or 6-mercaptopurine may increase the risk of blood disorder.

Storage:

- Store below 30°C, keep in dry place & protect from light.
- Keep out of the reach of children.

Packing:

Mesagut Tablet: Each box contains 30 tablets in alu-alu blister pack.



Manufactured by:
ARISTOPHARMA LTD.
Shampur-Kadamtali I/A, Dhaka-Bangladesh

20002318/01